Using reversed-phase liquid chromatography to monitor the sizes of Au/Pt core/shell nanoparticles.

Fu-Ken Liu,Yu-Cheng Chang

DOI: https://doi.org/10.1016/j.chroma.2010.01.032

IF: 4.601

2010-03-05

Journal of Chromatography A

Abstract:

What problem does this paper attempt to address?

Evaluation of 64Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates

Hiroki Matsumoto,Tadashi Watabe,Chika Igarashi,Tomoko Tachibana,Fukiko Hihara,Atsuo Waki,Ming-Rong Zhang,Hideaki Tashima,Taiga Yamaya,Kazuhiro Ooe,Eku Shimosegawa,Jun Hatazawa,Sei Yoshida,Kenichiro Naito,Hiroaki Kurihara,Makoto Ueno,Kimiteru Ito,Tatsuya Higashi,Yukie Yoshii

DOI: https://doi.org/10.3390/ph14100950

IF: 4.6

2021-09-23

Pharmaceuticals

Abstract:Objectives: To improve the prognosis of pancreatic cancer, new imaging methods to identify tumor lesions at a size of <1 cm are urgently needed. To approach this clinical issue, we developed a new method to detect small tumor lesions in the pancreas (≥3 mm) by positron emission tomography (PET) using an intraperitoneally (ip)-administered 64Cu-labeled new anti-epidermal growth factor receptor (EGFR) antibody (encoded as NCAB001), called 64Cu-NCAB001 ipPET. Methods: NCAB001 was manufactured under cGMP conditions and labeled with 64Cu. The radiochemical and biological properties of 64Cu-NCAB001 were evaluated. Tumor uptake of an ip-administered 64Cu-NCAB001 in mice with orthotopic pancreatic tumor xPA1-DC xenografts was also evaluated. Pharmacokinetics and radiation dosimetry were examined using PET images acquired after the ip administration of 64Cu-NCAB001 into cynomolgus monkeys with pharmacologic safety monitoring. Results: Radio-chromatography, cell-binding assays, and biodistribution of 64Cu-NCAB001 in mice were identical to those of our previous data with clinically available cetuximab. Small tumor lesions in the pancreas (≥3 mm) of mice could be identified by 64Cu-NCAB001 ipPET. The ip administration of 64Cu-NCAB001 into monkeys was safely conducted using ultrasound imaging. PET images in monkeys showed that ip-administered 64Cu-NCAB001 was distributed throughout the intraperitoneal cavity for up to 6 h and cleared thereafter. Most of the radioactivity was distributed in the liver and the large intestine. The radioactivity around the pancreas became negligible 24 h after administration. The estimated human effective dose was 0.0174 mSv/MBq. Conclusion: Our data support the initiation of clinical trials of 64Cu-NCAB001 ipPET to transfer this promising tool for the early diagnosis of pancreatic cancers.

pharmacology & pharmacy,chemistry, medicinal
Synthesis and biodistribution of 99Tcm-Cetuximab antibody for lung tumor targeted molecular imaging

Qing Xie,Hua Zhu,Shizhen Zhai,Puyun Chen,Yang Fan,Zhi Yang

DOI: https://doi.org/10.3760/cma.j.issn.2095-2848.2015.05.013

2015-01-01

Abstract:Objective To prepare and evaluate 99Tcm radiolabeled Cetuximab (C225) for imaging of EGFR specific binding.Methods Cetuximab antibody was reduced by 2-iminothiophene (2-IT).The radiolabeling of IT-Cetuximab with 99Tcm(99Tcm-IT-Cetuximab) was analyzed by HPLC,and was tested for in vitro stability and molecular integrity.The human lung cancer line (A549)-bearing nude mouse model was prepared for biodistribution and tumor targeted study.Tumor uptake was also measured by in vivo γ imaging.Results The labeling efficiency was 93.15％.The radiochemical purity was 96.46％ after purification.The in vitro stability was good in 5％ HSA,in which the radiochemical purity maintained above 80％ at 4 ℃ for 24 h.99Tcm-IT-Cetuximab showed good specific binding to tumor with peak uptake of (3.417±0.769) ％ID/g after 4 h.The T/NT ratio of blood increased to 1.454±0.174 at 24 h.γ imaging of A549-bearing nude mice xenografts also showed high T/NT ratio.Conclusions 99Tcm-IT-Cetuximab molecular probe could be prepared with high radiolabeling yield and radiochemical purity.It has excellent in vitro and in vivo stability,and shows specific uptake in A549 tumor.
177Lu-Labeled Antibodies for EGFR-targeted SPECT/CT Imaging and Radioimmunotherapy in a Preclinical Head and Neck Carcinoma Model.

Zhaofei Liu,Teng Ma,Hao Liu,Zhongxia Jin,Xianlei Sun,Huiyun Zhao,Jiyun Shi,Bing Jia,Fang Li,Fan Wang

DOI: https://doi.org/10.1021/mp4005047

2014-01-01

Molecular Pharmaceutics

Abstract:Epidermal growth factor receptor (EGFR) has been well characterized as an important target for cancer therapy. Immunotherapy based on EGFR-specific antibodies (e.g., panitumumab and cetuximab) has shown great clinical promise. However, increasing evidence has indicated that only a subgroup of patients receiving these antibodies will benefit from them, and even patients who do initially experience a major response may eventually develop therapeutic resistance. In this study, we investigated whether panitumumab and cetuximab can serve as delivery vehicles for tumor-targeted radionuclide therapy in a preclinical tumor model that did not respond to immunotherapy. The in vitro toxicity and cell binding properties of panitumumab and cetuximab were characterized. Both antibodies were conjugated with 1,4,7,10-tetraazadodecane-N,N',N",N"'-tetraacetic acid (DOTA) and radiolabeled with (177)Lu. Small-animal SPECT/CT, biodistribution, and radioimmunotherapy (RIT) studies of (177)Lu-DOTA-panitumumab ((177)Lu-Pan) and (177)Lu-DOTA-cetuximab ((177)Lu-Cet) were performed in the UM-SCC-22B tumor model. Both (177)Lu-Pan and (177)Lu-Cet exhibited favorable tumor targeting efficacy. The tumor uptake was 20.92 ± 4.45, 26.10 ± 5.18, and 13.27 ± 1.94% ID/g for (177)Lu-Pan, and 15.67 ± 3.84, 15.72 ± 3.49, and 7.82 ± 2.36% ID/g for (177)Lu-Cet at 24, 72, and 120 h p.i., respectively. RIT with a single dose of 14.8 MBq of (177)Lu-Pan or (177)Lu-Cet significantly delayed tumor growth. (177)Lu-Pan induced more effective tumor growth inhibition due to a higher tumor uptake. Our results suggest that panitumumab and cetuximab can function as effective carriers for tumor-targeted delivery of radiation, and that RIT is promising for targeted therapy of EGFR-positive tumors, especially for those tumors that are resistant to antibody-based immunotherapy.
Synthesis and evaluation of 64 Cu-radiolabeled NOTA-cetuximab ( 64 Cu-NOTA-C225) for immuno-PET imaging of EGFR expression.

Xiaoxia Xu,Teli Liu,Fei Liu,Xiaoyi Guo,Lei Xia,Qing Xie,Nan Li,Haifeng Huang,Xianteng Yang,Yangchun Xin,Hua Zhu,Zhi Yang

DOI: https://doi.org/10.21147/j.issn.1000-9604.2019.02.14

2019-01-01

Chinese Journal of Cancer Research

Abstract:Objective: Epidermal growth factor receptor (EGFR) is overexpressed in a wide variety of solid tumors, serving as a well-characterized target for cancer imaging or therapy. In this study, we aimed to design and synthesize a radiotracer, Cu-64-NOTA-C225, targeting EGFR for tumor positron emission tomography (PET) imaging. Methods: Cetuximab (C225) was conjugated to a bifunctional chelator, p-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), and further radiolabeled with copper-64 for PET imaging. Cu-64-NOTA-IgG and Cy5.5-C225 were also synthesized as control probes. A431 and A549 mouse models were established for micro-PET and/or near-infrared fluorescence (NIRF) imaging. Results: Cu-64-NOTA-C225 exhibited stability in vivo and in vitro up to 24 h and 50 h post-injection, respectively. A431 tumors with average standard uptake values (SUVs) of 5.61 +/- 0.69, 6.68 +/- 1.14, 7.80 +/- 1.51 at 6, 18 and 36 h post-injection, respectively, which were significantly higher than that of moderate EGFR expressing tumors (A549), with SUVs of 0.89 +/- 0.16, 4.70 +/- 0.81, 2.01 +/- 0.50 at 6, 18 and 36 h post-injection, respectively. The expression levels of A431 and A549 were confirmed by western blotting. Additionally, the tracer uptake in A431 tumors can be blocked by unlabeled cetuximab, suggesting that tracer uptake by tumors was receptor-mediated. Furthermore, NIRF imaging using Cy5.5-C225 showed that the fluorescence intensity in tumors increased with time, with a maximal intensity of 8.17E+10 (p/s/cm(2)/sr)/(mu W/cm(2)) at 48 h post-injection, which is consistent with the paradigm from micro-PET imaging in A431 tumor-bearing mice. Conclusions: The Cu-64-NOTA-C225 PET imaging may be able to specifically and sensitively differentiate tumor models with different EGFR expression levels. It offers potentials as a PET radiotracer for imaging of tracer EGFR-positive tumors.
Synthesis and preclinical investigation of 99mTc-p-SCN-Bzl-DTPA-cetuximab for targeting EGFR using head and neck squamous cell carcinoma (HNSCC) xenografts

Syed Qaiser Shah,Gul-E-Raana

DOI: https://doi.org/10.1007/s11033-019-04616-x

Abstract:To assess the preclinical potential of technetium-99m labelled conjugated para-isothiocyanato-benzyl diethylene triamine penta-acetic acid cetuximab (99mTc-p-SCN-Bzl-DTPA cetuximab) for imaging EGFR in HNSCC mice and rabbits xenografts. Cetuximab, a chimeric monoclonal antibody targeting EGFR, was conjugated with p-SCN-Bzl-DTPA followed by labelling with 99mTc. The labelled conjugate was evaluated for in vitro stability in L-cysteine at 37 °C. The 99mTc-p-SCN-Bzl-DTPA cetuximab was also investigated for immunoreactivity, internationalization kinetics, dose escalation (up to 300 µg) and biodistribution in HNSCC mice xenograft. The suitability of labelled moiety as a specific EGFR radio-tracer was assessed in HNSCC rabbit xenograft. 99mTc-p-SCN-Bzl-DTPA cetuximab exhibited more than 98% radiochemical purity at room temperature. In excess L-cysteine, it showed a stable behaviour at 37 °C up to 4 h p.l. The labelled conjugate was internalized in vitro in FaDu tumor cells up to 19.55%. Significantly higher uptake in tumor (at 10 µg; 34.75 ± 0.38% ID/g: pi) was seen in HNSCC mice xenograft with dose escalation assay from 1 to 300 µg/mouse. Blocking of EGFR with excess cetuximab consequently decreased the uptake of tumor up to 6.80 ± 1.25%. SPECT images of rabbit xenograft confirmed increase in tumor to background ratio after 4 h pi and validated its potential in preclinical trial as a specific FaDu tumor tracer. Our in vitro and in vivo preclinical findings indicate that the 99mTc-p-SCN-Bzl-DTPA cetuximab prepared at optimal dose of cetuximab could become a useful tool for EGFR imaging in HNSCC using SPECT.
PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma.

Kayvan Sadri,Qing Ren,Kaijun Zhang,Bishnuhari Paudyal,Devakumar Devadhas,Ulrich Rodeck,Mathew Thakur

DOI: https://doi.org/10.1097/MNM.0b013e3283419523

2011-01-01

Nuclear Medicine Communications

Abstract:BACKGROUND AND OBJECTIVE:Cetuximab is a monoclonal antibody that binds to and inhibits the epidermal growth factor receptor (EGFR). EGFR overexpression has been observed in a subset of breast cancers. The purpose of this study was to evaluate 64Cu-labeled cetuximab as an imaging agent using MDA-MB-468 breast cancer cells. METHODS:Cetuximab was coupled with an N-sulfosuccinimide ester of DOTA, purified, and labeled with the positron-emitting nuclide, 64Cu. Receptor-binding specificity and affinity of 64Cu-DOTA-cetuximab were studied using human MDA-MB-468 breast cancer cells, which express high levels of EGFR. Micropositron emission tomography and biodistribution studies were performed in athymic nude mice bearing MDA-MB-468 cell xenografts. Blocking studies with cold cetuximab were also performed to determine the specific binding of cetuximab. RESULTS:The radiochemical yield was 97.1 ± 1.1%. The specific activity was 1.5 Ci/μm cetuximab and the affinity to EGFR-positive MDA-MB-468 cells was high (KD=0.4 nmol/l). Both biodistribution and micropositron emission tomographic imaging studies with 64Cu-DOTA-cetuximab showed higher tumor uptake at 24 h (20.91 ± 2.49% ID/g, standardized uptake values of 9.6) than at 4 h (11.65 ± 3.89% ID/g, standardized uptake values of 4.9). Tumor uptake was significantly reduced from 20.91 ± 2.49% ID/g at 24 h to 14.42 ± 0.85% ID/g in a 1-h blocking study (P=0.00). CONCLUSION:Cetuximab can be labeled with 64Cu without compromising its biological activity. The tumor uptake was excellent with high tumor/muscle (7.97 ± 1.78 at 4 h, 15.91 ± 6.04 at 24 h) and reasonable tumor/blood (0.5 ± 0.18 at 4 h, 2.12 ± 0.86 at 24 h) ratios. Blocking studies showed the specific binding of the labeled antibody to tumor tissue.
Matching The Decay Half-Life With The Biological Half-Life: Immunopet Imaging With Sc-44-Labeled Cetuximab Fab Fragment

Rubel Chakravarty,Shreya Goel,Hector F. Valdovinos,Reinier Hernandez,Hao Hong,Robert J. Nickles,Weibo Cai

DOI: https://doi.org/10.1021/bc500415x

IF: 4.7

2014-01-01

Bioconjugate Chemistry

Abstract:Scandium-44 (t(1/2) = 3.9 h) is a relatively new radioisotope of potential interest for use in clinical positron emission tomography (PET). Herein, we report, for the first time, the room-temperature radiolabeling of proteins with (44)Sc for in vivo PET imaging. For this purpose, the Fab fragment of Cetuximab, a monoclonal antibody that binds with high affinity to epidermal growth factor receptor (EGFR), was generated and conjugated with N-[(R)-2-amino-3-(para-isothiocyanato-phenyl)propyl]-trans-(S,S)-cyclohexane-1,2-diamine-N,N,N',N?,N?-pentaacetic acid (CHX-A?-DTPA). The high purity of Cetuximab-Fab was confirmed by SDS-PAGE and mass spectrometry. The potential of the bioconjugate for PET imaging of EGFR expression in human glioblastoma (U87MG) tumor-bearing mice was investigated after (44)Sc labeling. PET imaging revealed rapid tumor uptake (maximum uptake of similar to 12% ID/g at 4 h postinjection) of Sc-44-CHX-A"-DTPA-Cetuximab-Fab with excellent tumor-to-background ratio, which might allow for same day PET imaging in future clinical studies. Immunofluorescence staining was conducted to correlate tracer uptake in the tumor and normal tissues with EGFR expression. This successful strategy for immunoPET imaging of EGFR expression using Sc-44-CHX-A"-DTPA-Cetuximab-Fab can make clinically translatable advances to select the right population of patients for EGFR-targeted therapy and also to monitor the therapeutic efficacy of anti-EGFR treatments.
Affibody Molecule for Positron Emission Tomography Imaging of Human Epidermal Growth Factor Receptor: Validation in Mouse Models and Human Cancer Tissues

Weizhi Chen,Shuang Miao,Yao Sun,Yang Liu,Chunhe Wang,Xiang Liu,Zhen Cheng,Xilin Sun

DOI: https://doi.org/10.21203/rs.3.rs-1024214/v1

2021-11-02

Abstract:Abstract Background: Tumor heterogeneity and changes in epidermal growth factor receptor (EGFR) expression status over time post challenges for the design of strategies for effective anti-EGFR monoclonal antibodies in the treatment of non-small-cell lung cancer (NSCLC). Therefore, there is an urgent need to develop techniques for real-time and comprehensive tumor EGFR profiling especially in lung cancer precision medicine trials. Radionuclide imaging of EGFR expression in tumors may screen patients for EGFR-targeting therapies and predict response or resistance to certain treatments. Methods: EGFR-specific Affibody molecule (Z EGFR:1907 ) was radiolabeled with 68 Ga. The radioligands were characterized in vitro and in mice bearing subcutaneous tumors with varying levels of EGFR expression: HCC827 (EGFR overexpression), H1975 (moderate-high), A549 (moderate), H358 (low), and H520 (negative). In vivo tumor targeting activity using PET imaging and biodistribution were conducted in tumor-bearing nude mice. Autoradiography, western blot, immunofluorescence, and immunohistochemistry were performed in human tumor samples. Statistical analyses were performed using GraphPad Prism 7.0. One-way or two-way analysis of variance (ANOVA) followed by the Bonferroni’s multiple comparisons test was used. Statistical significance was set at P < 0.05. Results: 68 Ga-NOTA-Z EGFR:1907 showed higher uptake in high EGFR-expressing cells (HCC827, H1975) when compared to cells with moderate to low EGFR (A549, H358) or without EGFR (H520). Radionuclide imaging showed probe accumulation was preferential in EGFR-expressing tumors, particularly in HCC827, H1975 xenografts. A549 and H358 xenografts were mildly and indistinctly visualized. EGFR-negative H520 xenografts were barely visible at any time-point. Biodistribution showed a significantly higher accumulation in HCC827 tumors when compared to H520 tumors (3.20 ± 0.10 %ID/g vs. 0.81 ± 0.08 %ID/g at 2h, P < 0.05). Specific binding to EGFR could be competitively blocked by excess un-radiolabeled affibody molecules in cell uptake, PET imaging and biodistribution assays. Autoradiography showed the regions with high radiotracer uptake partly overlapped with the area of positive EGFR immunofluorescence and immunohistochemistry. Finally, the overall accumulation of autoradiography was positively correlated with immunohistochemistry score. Conclusion: Affibody-based radiotracer 68 Ga-NOTA-Z EGFR:1907 is suitable for identification of EGFR expression, showing great potential for further applications and clinical translation.
Cetuximab-conjugated Iodine Doped Carbon Dots As a Dual Fluorescent/ct Probe for Targeted Imaging of Lung Cancer Cells.

Huifang Su,Ying Liao,Fengshou Wu,Xinzhi Sun,Hongjian Liu,Kai Wang,Xunjin Zhu

DOI: https://doi.org/10.1016/j.colsurfb.2018.06.014

2018-01-01

Abstract:Iodine doped carbon quantum dots (I-CQDs) have been synthesized by a facile one-pot hydrothermal method using citric acid and iohexol as precursors. The morphology and chemical structures of I-CQDs are investigated by TEM, XRD, XPS, and FTIR spectroscopy. The as-prepared I-CQDs exhibit excitation-dependent PL behavior with the emission quantum yield of 18%. The presence of iodine ions in I-CQDs is confirmed by XPS spectrum, which endows the composite with CT imaging performance. Thus, they could be used as efficient probes for fluorescence/CT bimodal imaging. To realize a precise diagnosis of tumor lesions, the surface of I-CQDs is conjugated with a targeting molecular (cetuximab) to afford I-CQDs-C225. The MTT assay against three kinds of human cell lines verifies the low cytotoxicity of I-CQDs-C225. The targeting ability of I-CQDs-C225 are evaluated in vitro using HCC827 cells (lung cancer cell line, over-expression of EGFR), H23 (lung cancer cell line, low expression of EGFR) and HLF cells (lung normal cell line, low expression of EGFR) via a confocal laser scanning microscope. The results show that HCC827 cells exhibited strong fluorescence, indicating the cetuximab-conjugated I-CQDs could target specifically the cancer cells with over-expression of EGFR via EGFR mediated endocytosis.
Radiolabeling and Preclinical Evaluation of Therapeutic Efficacy of 225Ac-ch806 in Glioblastoma and Colorectal Cancer Xenograft Models

Christian W. Wichmann,Katherine A. Morgan,Zhipeng Cao,Laura D. Osellame,Nancy Guo,Hui Gan,Edward Reilly,Ingrid J.G. Burvenich,Graeme J. O’Keefe,Paul S. Donnelly,Andrew M. Scott

DOI: https://doi.org/10.2967/jnumed.123.266894

2024-09-04

Journal of Nuclear Medicine

Abstract:The epidermal growth factor receptor (EGFR) protein is highly expressed in a range of malignancies. Although therapeutic interventions directed toward EGFR have yielded therapeutic responses in cancer patients, side effects are common because of normal-tissue expression of wild-type EGFR. We developed a novel tumor-specific anti-EGFR chimeric antibody ch806 labeled with 225 Ac and evaluated its in vitro properties and therapeutic efficacy in murine models of glioblastoma and colorectal cancer. Methods: 225 Ac-ch806 was prepared using different chelators, yielding [ 225 Ac]Ac-macropa-tzPEG 3 Sq-ch806 and [ 225 Ac]Ac-DOTA-dhPzPEG 4 -ch806. Radiochemical yield, purity, apparent specific activity, and serum stability of 225 Ac-ch806 were quantified. In vitro cell killing effect was examined. The biodistribution and therapeutic efficacy of 225 Ac-ch806 were investigated in mice with U87MG.de2-7 and DiFi tumors. Pharmacodynamic analysis of tumors after therapy was performed, including DNA double-strand break immunofluorescence of H2AX, as well as immunohistochemistry for proliferation, cell cycle arrest, and apoptosis. Results: [ 225 Ac]Ac-macropa-tzPEG 3 Sq-ch806 surpassed [ 225 Ac]Ac-DOTA-dhPzPEG 4 -ch806 in radiochemical yield, purity, apparent specific activity, and serum stability. [ 225 Ac]Ac-macropa-tzPEG 3 Sq-ch806 was therefore used for both in vitro and in vivo studies. It displayed a significant, specific, and dose-dependent in vitro cell-killing effect in U87MG.de2-7 cells. 225 Ac-ch806 also displayed high tumor uptake and minimal uptake in normal tissues. 225 Ac-ch806 significantly inhibited tumor growth and prolonged survival in both U87MG.de2-7 and DiFi models. Enhanced H2AX staining was observed in 225 Ac-ch806–treated tumors compared with controls. Reduced Ki-67 expression was evident in all 225 Ac-ch806–treated tumors. Increased expression of p21 and cleaved caspase 3 was shown in U87MG.de2-7 and DiFi tumors treated with 225 Ac-ch806. Conclusion: In glioblastoma and colorectal tumor models, 225 Ac-ch806 significantly inhibited tumor growth via induction of double-strand breaks, thereby constraining cancer cell proliferation while inducing cell cycle arrest and apoptosis. These findings underscore the potential clinical applicability of 225 Ac-ch806 as a potential therapy for EGFR-expressing solid tumors.

radiology, nuclear medicine & medical imaging
SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression

Lieven Huang,Lea Olive Tchouate Gainkam,Vicky Caveliers,Chris Vanhove,Marleen Keyaerts,Patrick De Baetselier,Axel Bossuyt,Hilde Revets,Tony Lahoutte

DOI: https://doi.org/10.1007/s11307-008-0133-8

2008-02-23

Molecular Imaging and Biology

Abstract:PurposeOverexpression of the epidermal growth factor receptor (EGFR) occurs with high incidence in various carcinomas. The oncogenic expression of the receptor has been exploited for immunoglobulin-based diagnostics and therapeutics. We describe the use of a llama single-domain antibody fragment, termed Nanobody®, for the in vivo radioimmunodetection of EGFR overexpressing tumors using single photon emission computed tomography (SPECT) in mice.MethodsFluorescence-activated cell sorting (FACS) analysis was performed to evaluate the specificity and selectivity of 8B6 Nanobody to bind EGFR on EGFR overexpressing cells. The Nanobody was then labeled with 99mTc via its C-terminal histidine tail. Uptake in normal organs and tissues was assessed by ex vivo analysis. In vivo tumor targeting of 99mTc-8B6 Nanobody was evaluated via pinhole SPECT in mice bearing xenografts of tumor cells with either high (A431) or moderate (DU145) overexpression of EGFR.ResultsFACS analysis indicated that the 8B6 Nanobody only recognizes cells overexpressing EGFR. In vivo blood clearance of 99mTc-8B6 Nanobody is relatively fast (half-life, 1.5 h) and mainly via the kidneys. At 3 h postinjection, total kidney accumulation is high (46.6 ± 0.9%IA) compared to total liver uptake (18.9 ± 0.6%IA). Pinhole SPECT imaging of mice bearing A431 xenografts showed higher average tumor uptake (5.2 ± 0.5%IA/cm3) of 99mTc-8B6 Nanobody compared to DU145 xenografts (1.8 ± 0.3%IA/cm3, p < 0.001).ConclusionThe EGFR-binding Nanobody investigated in this study shows high specificity and selectivity towards EGFR overexpressing cells. Pinhole SPECT analysis with 99mTc-8B6 Nanobody enabled in vivo discrimination between tumors with high and moderate EGFR overexpression. The favorable biodistribution further corroborates the suitability of Nanobodies for in vivo tumor imaging.

radiology, nuclear medicine & medical imaging
Initial Evaluation of 99m Tc-labeled Anti-Carcinoembryonic Antigen Single-Chain Fragment Variable for Micro-Single-photon Emission Computed Tomography Imaging in Mice with Colorectal Cancer.

Xue Qin,Xiangxi Meng,Yao Xiong,Xiaoyi Guo,Yanan Ren,Li Wen,Qian Zhang,Hua Zhu,Zhi Yang

DOI: https://doi.org/10.1002/jlcr.3960

2022-01-01

Abstract:Carcinoembryonic antigen (CEA) has emerged as an important molecular target for several neoplastic diseases, including colorectal cancer with CEA over-expression. In this study, we report the production and radiolabeling of a novel anti-CEA single-chain fragment variable (scFv-96NRT, concentration for 50% of maximal effect 46 ng/ml), and evaluation of [Tc-99m]Tc-scFv-96NRT in non-invasive detection of CEA expression. [Tc-99m]Tc-scFv-96NRT was synthesized by one step reduction in labeling yield of >95% with radiochemical purity of >98% and molar activity of 10-11 GBq/mu mol. [Tc-99m]Tc-scFv-96NRT showed high stability in 0.01 M phosphate-buffered saline (PBS) and 5% human serum albumin (HSA). It exhibited elevated uptake in CEA over-expressing cells. Biodistribution studies in BALB/c mice revealed that the probe was cleared from blood rapidly, and the highest retention was observed in the kidneys. The micro-single-photon emission computed tomography (micro-SPECT) imaging of [Tc-99m]Tc-scFv-96NRT showed a specific accumulation pattern, as blocking experiment with excess scFv-96NRT suppressed the tumor uptake. These preliminary results suggest that [Tc-99m]Tc-scFv-96NRT is a potential non-invasive molecular probe for imaging tumors with CEA over-expression.
A Pretargeted Imaging Strategy for EGFR-Positive Colorectal Carcinoma Via Modulation of Tz-Radioligand Pharmacokinetics.

Lin Qiu,Qingyu Lin,Zhan Si,Hui Tan,Guobing Liu,Jun Zhou,Tingting Wang,Yue Chen,Yingzhao Huang,Tao Yu,Mingzhi Jin,Dengfeng Cheng,Hongcheng Shi

DOI: https://doi.org/10.1007/s11307-020-01539-z

2020-01-01

Molecular Imaging and Biology

Abstract:Purpose Previously, we successfully developed a pretargeted imaging strategy (atezolizumab-TCO/[ 99m Tc]HYNIC-PEG 11 -Tz) for evaluating programmed cell death ligand-1 (PD-L1) expression in xenograft mice. However, the surplus unclicked [ 99m Tc]HYNIC-PEG 11 -Tz is cleared somewhat sluggishly through the intestines, which is not ideal for colorectal cancer (CRC) imaging. To shift the excretion of the Tz-radioligand to the renal system, we developed a novel Tz-radioligand by adding a polypeptide linker between HYNIC and PEG 11 . Procedures Pretargeted molecular probes [ 99m Tc]HYNIC-polypeptide-PEG 11 -Tz and cetuximab-TCO were synthesized. [ 99m Tc]HYNIC-polypeptide-PEG 11 -Tz was evaluated for in vitro stability and in vivo blood pharmacokinetics. In vitro ligation reactivity of [ 99m Tc]HYNIC-polypeptide-PEG 11 -Tz towards cetuximab-TCO was also tested. Biodistribution assay and imaging of [ 99m Tc]HYNIC-polypeptide-PEG 11 -Tz were performed to observe its excretion pathway. Pretargeted biodistribution was measured at three different accumulation intervals to determine the optimal pretargeted interval time. Pretargeted (cetuximab-TCO 48 h/[ 99m Tc]HYNIC-PEG 11 -Tz 6 h) and (cetuximab-TCO 48 h/[ 99m Tc]HYNIC-Polypeptide-PEG 11 -Tz 6 h) imagings were compared to examine the effect of the excretion pathway on tumor imaging. Results [ 99m Tc]HYNIC-polypeptide-PEG 11 -Tz showed favorable in vitro stability and rapid blood clearance in mice. SEC-HPLC revealed almost complete reaction between cetuximab-TCO and [ 99m Tc]HYNIC-polypeptide-PEG 11 -Tz in vitro , with the 8:1 Tz-to-mAb reaction providing a conversion yield of 87.83 ± 3.27 %. Biodistribution and imaging analyses showed that the Tz-radioligand was cleared through the kidneys. After 24, 48, and 72 h of accumulation in HCT116 tumor, the tumor-to-blood ratio of cetuximab-TCO was 0.83 ± 0.13, 1.40 ± 0.31, and 1.15 ± 0.21, respectively. Both pretargeted (cetuximab-TCO 48 h/[ 99m Tc]HYNIC-PEG 11 -Tz 6 h) and (cetuximab-TCO 48 h/[ 99m Tc]HYNIC-polypeptide-PEG 11 -Tz 6 h) clearly delineated HCT116 tumor. Pretargeted imaging strategy using cetuximab-TCO/[ 99m Tc]HYNIC-polypeptide-PEG 11 -Tz could be used for diagnosing CRC, as the surplus unclicked [ 99m Tc]HYNIC-polypeptide-PEG 11 -Tz was cleared through the urinary system, leading to low abdominal uptake background. Conclusion Our novel pretargeted imaging strategy (cetuximab-TCO/[ 99m Tc]HYNIC-polypeptide-PEG 11 -Tz) was useful for imaging CRC, broadening the application scope of pretargeted imaging strategy. The pretargeted imaging strategy clearly delineated HCT116 tumor, showing that its use could be extended to selection of internalizing antibodies.
Initial evaluation of 99m Tc‐labeled anti‐CEA scFv for micro‐SPECT imaging in mice with colorectal cancer

Xue Qin,Xiangxi Meng,Yao Xiong,Xiaoyi Guo,Yanan Ren,Li Wen,Qian Zhang,Hua Zhu,Yang Zhi

DOI: https://doi.org/10.1002/jlcr.3960

2021-01-01

Journal of Labelled Compounds and Radiopharmaceuticals

Abstract:Carcinoembryonic antigen (CEA) has emerged as an important molecular target for several neoplastic diseases, including colorectal cancer with CEA over-expression. In this study, we report the production and radiolabeling of a novel anti-CEA single-chain fragment variable (scFv-96NRT, concentration for 50% of maximal effect 46 ng/ml), and evaluation of [99m Tc]Tc-scFv-96NRT in non-invasive detection of CEA expression. [99m Tc]Tc-scFv-96NRT was synthesized by one step reduction in labeling yield of >95% with radiochemical purity of >98% and molar activity of 10-11 GBq/μmol. [99m Tc]Tc-scFv-96NRT showed high stability in 0.01 M phosphate-buffered saline (PBS) and 5% human serum albumin (HSA). It exhibited elevated uptake in CEA over-expressing cells. Biodistribution studies in BALB/c mice revealed that the probe was cleared from blood rapidly, and the highest retention was observed in the kidneys. The micro-single-photon emission computed tomography (micro-SPECT) imaging of [99m Tc]Tc-scFv-96NRT showed a specific accumulation pattern, as blocking experiment with excess scFv-96NRT suppressed the tumor uptake. These preliminary results suggest that [99m Tc]Tc-scFv-96NRT is a potential non-invasive molecular probe for imaging tumors with CEA over-expression.
The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188Re-herceptin

Guiping Li,Yongxian Wang,Kai Huang,Hui Zhang,Wuhe Peng,Chunfu Zhang

DOI: https://doi.org/10.1016/j.nucmedbio.2004.09.003

Abstract:The therapeutic efficacy of radioimmunotherapy (RIT) of 188Re-labeled herceptin, which is a humanized anti-p185-HER2/neu monoclonal antibody (mAb), was studied. The nude mice bearing nasopharyngeal carcinoma (NPC) expressing HER2/neu protooncogene were injected with 188Re-herceptin intratumorally and intravenously. The biodistribution was observed on day 2 (n = 3). The tumor growth inhibition rate (IR) was determined by measurement of tumor volume. In the intratumorally treated mice, tumor uptake of 188Re-herceptin was significantly greater than in the intravenously treated mice [11.53% injected dose (ID)/g vs. 2.79% ID/g at 48 h], and lower normal organ uptake was also seen. The intratumoral administration of 188Re-herceptin caused greater inhibition of tumor growth at the fourth week as compared to the intravenous administration. It is concluded that intratumoral administration of 188Re-herceptin makes high level of radioactivity retained in tumor with significantly lower radioactivity retained in normal tissues, and provides a more effective regional therapy for NPC overexpressing HER2/neu.
Dilating Venous Diseases: Varicocele and Varicose Vein.

E. Yetkın,S. Ozturk

DOI: https://doi.org/10.1016/j.avsg.2016.09.004

IF: 1.5

Annals of Vascular Surgery

Abstract:
Radioimmunoimaging of Lung Adenocarcinoma in Nude Mice Using Rhenium-186 Labeled with Monoclonal Antibody

Jian Lü

2002-01-01

Abstract:Objective: A method of rbenium-186( 186 Re) labeled with monoclonal antibody was established. Biodistribution of tracer 186 Re-McAb in nude mice was studied. Methods: We used ascorbic acid (AA) in reducting the antibody disulfide grups to sulfhydryls and SnCl 2 in citric acid for the reduction of 186 ReO - 4. Results: The labeling yields as determined by instant thin-layer chromatography were greater than 96%. The labeled antibody was stable when challenged with 250-fold molar excess of DTPA and HSA for 24 hours at 37℃. The immunoreactivity of 186 Re-McAb was more than 90% in vitro. Immunoscintigraphy showed significant tumor uptake 48 hours after injection and tumors could be imaged at the 24th to 48th hour. The best images were obtained at the 48th hour.Conclusion: Rhenium-186 labeled with McAb is ideal to cancer radioimmunodiagnosis and radioimmunotherapy.
Loudness , Its Definition , Measurement and Calculation

W. A. Mvnso,Bell Laboratories

Abstract:OUDNESS is a psychological term Used to describe the magnitude of an auditory sensation. Although we use the terms "very loud," "loud," "moderately loud," "soft" and "very soft," corresponding to the musical notations if, f, m f, p, and pp, to define the magnitude, it is evident that these terms are not at all precise and depend upon the experience, the auditory acuity, and the customs of the persons using them. If loudness depended only upon the intensity of the sound wave producing the loudness, then measurements of the physical intensity would definitely determine the loudness as sensed by a typical individual and therefore could be used as a precise means of defining it. However, no such simple relation exists. The magnitude of an auditory sensation, that is, the loudness of the sound, is probably dependent upon the total number of nerve impulses that reach the brain per second along the auditory tract. It is evident that these auditory phenomena are dependent not alone upon the intensity of the sound but also upon their physical composition. For example, if a person listened to a flute and then to a bass drum placed at such distances that the sounds coming from the two instruments are judged to be equally loud, then, the intensity of the sound at the ear produced by the bass drum would be many times that produced by the flute. If the composition of the sound, that is, its wave form, is held constant, but its intensity at the ear of the listener varied, then the loudness produced will be the same for the same intensity only if the same or an equivalent ear is receiving the sound and also only if the listener is in the same psychological and physiological conditions, with reference to fatigue, attention, alertness, etc. Therefore, in order to determine the loudness produced, it is necessary to define the intensity of the sound, its physical composition, the kind of ear receiving it, and the physiological and psychological conditions of the listener. In most engineering problems we are interested mainly in the effect upon a typical observer who is in a typical condition for listening. In a paper during 1921 one of us suggested using the number of decibels above threshold as a measure of loudness and some experimental data were presented on this basis. As more data were accumulated it was evident that such a basis for
Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC

Yang Zhang,Jie Yang,Manhua Ding,Liantao Li,Zheng Lu,Qing Zhang,Junnian Zheng

DOI: https://doi.org/10.3892/ol.2016.5081

2016-09-02

Oncology Letters

Abstract:Lung cancer is the leading cause of cancer-associated mortality, worldwide. For this reason, novel therapies are required for the treatment of this devastating disease. Cetuximab is a monoclonal antibody against epidermal growth factor receptor (EGFR), which is overexpressed in a variety of solid tumors, including non-small cell lung cancer (NSCLC). The therapeutic efficacy of cetuximab for NSCLC is limited to use as a monotherapy or in combination with chemotherapy. The objective of the present study was to develop a novel strategy to enhance the therapeutic efficacy of cetuximab for NSCLC by a co-administration with the tumor-penetrating internalizing RGD peptide (iRGD). Human NSCLC subcutaneous xenograft models established with the A549 cell line in nude mice were treated with 30 mg/kg cetuximab, 4 mg/kg iRGD, cetuximab plus iRGD or phosphate-buffered saline. The tumor-penetration, <i>in vivo</i> therapeutic efficacy and involved mechanism were evaluated. The present study showed that the A549 xenograft model is sensitive to the co-administration of cetuximab and iRGD. Treatment with cetuximab plus iRGD resulted in a significant increase in the tumor-penetration of cetuximab and tumor reduction compared with cetuximab monotherapy. In conclusion, iRGD enhances the effects of co-administered cetuximab in an NSCLC model. The combined application of cetuximab and iRGD may be a novel strategy to enhance the clinical therapeutic efficacy of cetuximab for the treatment of NSCLC.

oncology
Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen

Hao Hong,Jiangtao Sun,Weibo Cai

DOI: https://doi.org/10.4137/bmi.s1124

2008-01-01

Biomarker Insights

Abstract:Carcinoembryonic antigen (CEA), highly expressed in many cancer types, is an important target for cancer diagnosis and therapy. Radionuclide-based imaging techniques (gamma camera, single photon emission computed tomography [SPECT] and positron emission tomography [PET]) have been extensively explored for CEA-targeted cancer imaging both preclinically and clinically. Briefly, these studies can be divided into three major categories: antibody-based, antibody fragment-based and pretargeted imaging. Radiolabeled anti-CEA antibodies, reported the earliest among the three categories, typically gave suboptimal tumor contrast due to the prolonged circulation life time of intact antibodies. Subsequently, a number of engineered anti-CEA antibody fragments (e.g. Fab’, scFv, minibody, diabody and scFv-Fc) have been labeled with a variety of radioisotopes for CEA imaging, many of which have entered clinical investigation. CEA-Scan (a 99mTc-labeled anti-CEA Fab’ fragment) has already been approved by the United States Food and Drug Administration for cancer imaging. Meanwhile, pre-targeting strategies have also been developed for CEA imaging which can give much better tumor contrast than the other two methods, if the system is designed properly. In this review article, we will summarize the current state-of-the-art of radionuclide-based cancer imaging targeting CEA. Generally, isotopes with short half-lives (e.g. 18F and 99mTc) are more suitable for labeling small engineered antibody fragments while the isotopes with longer half-lives (e.g. 123I and 111In) are needed for antibody labeling to match its relatively long circulation half-life. With further improvement in tumor targeting efficacy and radiolabeling strategies, novel CEA-targeted agents may play an important role in cancer patient management, paving the way to “personalized medicine”.

Using reversed-phase liquid chromatography to monitor the sizes of Au/Pt core/shell nanoparticles.

Evaluation of 64Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates

Synthesis and biodistribution of 99Tcm-Cetuximab antibody for lung tumor targeted molecular imaging

177Lu-Labeled Antibodies for EGFR-targeted SPECT/CT Imaging and Radioimmunotherapy in a Preclinical Head and Neck Carcinoma Model.

Synthesis and evaluation of 64 Cu-radiolabeled NOTA-cetuximab ( 64 Cu-NOTA-C225) for immuno-PET imaging of EGFR expression.

Synthesis and preclinical investigation of 99mTc-p-SCN-Bzl-DTPA-cetuximab for targeting EGFR using head and neck squamous cell carcinoma (HNSCC) xenografts

PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma.

Matching The Decay Half-Life With The Biological Half-Life: Immunopet Imaging With Sc-44-Labeled Cetuximab Fab Fragment

Affibody Molecule for Positron Emission Tomography Imaging of Human Epidermal Growth Factor Receptor: Validation in Mouse Models and Human Cancer Tissues

Cetuximab-conjugated Iodine Doped Carbon Dots As a Dual Fluorescent/ct Probe for Targeted Imaging of Lung Cancer Cells.

Radiolabeling and Preclinical Evaluation of Therapeutic Efficacy of 225Ac-ch806 in Glioblastoma and Colorectal Cancer Xenograft Models

SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression

Initial Evaluation of 99m Tc-labeled Anti-Carcinoembryonic Antigen Single-Chain Fragment Variable for Micro-Single-photon Emission Computed Tomography Imaging in Mice with Colorectal Cancer.

A Pretargeted Imaging Strategy for EGFR-Positive Colorectal Carcinoma Via Modulation of Tz-Radioligand Pharmacokinetics.

Initial evaluation of 99m Tc‐labeled anti‐CEA scFv for micro‐SPECT imaging in mice with colorectal cancer

The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188Re-herceptin

Dilating Venous Diseases: Varicocele and Varicose Vein.

Radioimmunoimaging of Lung Adenocarcinoma in Nude Mice Using Rhenium-186 Labeled with Monoclonal Antibody

Loudness , Its Definition , Measurement and Calculation

Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC

Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen